Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of P1101 + Ribavirin in HCV Genotype 2
NCT04774107Phase 1Completed
- Sponsor
- PharmaEssentia
- Start
- Nov 2020
- Primary completion
- Jul 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ropeginterferon alfa-2b in hepatitis C (HCV), sponsored by PharmaEssentia. Primary endpoint: Amount of P1101 in the blood stream. Started Nov 2020; status: completed.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT04774107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04774107.